8-K: IN8bio Reports Strong Q2 2025, GBM Trial Shows 4-Year PFS

IN8bio announced positive Q2 2025 financial results and significant clinical milestones, including a glioblastoma patient achieving over four years of progression-free survival with INB-200.

Summary

• Reported second quarter 2025 financial results and recent business highlights.
• A patient in the INB-200 clinical trial for glioblastoma (GBM) has surpassed four years without progression, a significant milestone for front-line, grade IV GBM.
• Presented positive new data at ASCO 2025 showing GBM patients receiving multiple doses of INB-200 achieved a median progression-free survival (mPFS) of 16.1 months, more than double the 6.9 months typically observed with standard-of-care Stupp protocol.
• 40% of patients receiving multiple doses of INB-200 remain progression-free for over 18 months with no significant toxicities as of May 31, 2025.
• Received the Host Region USA East Abstract Award at ISCT 2025 for the DeltEx manufacturing platform, highlighting robust and scalable cell therapy production.
• Presented new preclinical data at ASGCT 2025 for INB-619, a novel gamma-delta T cell engager, demonstrating complete, targeted depletion of harmful B cells in lupus samples without significant inflammatory cytokines.
• Extended cash runway into June 2026.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical data, particularly the durable four-year PFS in glioblastoma and the significant improvement in mPFS over standard of care. Financially, the company demonstrated improved efficiency with reduced net loss and extended cash runway. These factors indicate strong progress and increased confidence in the company's pipeline and financial management.

Positives

• Achieved a durable four-year progression-free survival (PFS) milestone in a patient with front-line, grade IV glioblastoma (GBM) treated with INB-200.
• INB-200 demonstrated a median progression-free survival (mPFS) of 16.1 months in multiple-dose GBM patients, significantly exceeding the 6.9 months observed with standard-of-care Stupp protocol.
• 40% of multiple-dose INB-200 patients remained progression-free for over 18 months with no significant toxicities.
• Received the Host Region USA East Abstract Award at ISCT 2025 for the innovative and scalable DeltEx manufacturing platform.
• Preclinical data for INB-619 showed complete, targeted depletion of harmful B cells in lupus samples without significant inflammatory cytokines, suggesting a potentially safer immunotherapy for autoimmune diseases.
• Net loss significantly reduced to $5.1 million in Q2 2025 from $8.6 million in Q2 2024.
• Research and Development (R&D) expenses decreased to $2.5 million in Q2 2025 from $5.2 million in Q2 2024, reflecting strategic pipeline prioritization.
• General and Administrative (G&A) expenses decreased to $2.7 million in Q2 2025 from $3.5 million in Q2 2024 due to cost savings.
• Cash position increased to $13.2 million as of June 30, 2025, compared to $10.2 million in the prior year.
• Cash runway extended into June 2026.

Negatives

• Strategic pause on clinical trial-related activities for the INB-400 program, which contributed to reduced R&D expenses.

Risks

• Risks to site initiation, clinical trial commencement, patient enrollment, and follow-up, as well as the ability to meet anticipated deadlines and milestones.
• Uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of product candidates.
• Risk of being unable to raise additional capital, potentially leading to delays, further reductions, or exploration of other strategic options for development programs, or even termination of operations.
• Ability to continue to operate as a going concern.
• Risk of not realizing the intended benefits of the DeltEx platform.
• Uncertainty regarding the availability and timing of results from preclinical studies and clinical trials.
• Whether the outcomes of preclinical studies will be predictive of clinical trial results.
• Whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials.
• Risk that trials and studies may be delayed and may not have satisfactory outcomes.
• Potential adverse effects arising from the testing or use of product candidates.
• Uncertainty of regulatory approvals to conduct trials or to market products.
• Reliance on third parties, including licensors and clinical research organizations.

Future Outlook

The company anticipates providing updates on enrollment in the INB-100 expansion cohort for leukemia patients, further clinical updates from INB-200 and INB-400 glioblastoma clinical trials, and additional preclinical data from the INB-619 T cell engager program for cancer and autoimmune diseases in Q4 2025. The company has also extended its cash runway into June 2026.

Management Comments

• "We believe this quarter clearly demonstrates our ability to deliver transformative outcomes in cancer and autoimmune disease."
• "We had an oral presentation at ASCO, reached a remarkable four-year PFS milestone in a grade IV glioblastoma patient, demonstrated the potential of our T cell engager platform to treat autoimmune diseases, and highlighted our robust cell therapy manufacturing capabilities."
• "We're proud of these continued accomplishments, which demonstrate our ability to be a leader in gamma-delta T cell therapies and highlight our potential to help transform the treatment of cancer and autoimmune disease."
• "We've also extended our runway into June 2026."

Industry Context

This announcement positions IN8bio as a significant player in the rapidly evolving gamma-delta T cell therapy space, targeting both oncology (glioblastoma, leukemia) and autoimmune diseases (lupus). The durable clinical response in glioblastoma, a notoriously difficult-to-treat cancer, is a standout achievement that could differentiate its platform. The preclinical data in autoimmune diseases also signals a strategic expansion into a broader market, leveraging the unique properties of gamma-delta T cells for targeted B cell depletion, potentially offering a safer alternative to existing immunotherapies. The recognition for its manufacturing platform underscores the importance of scalable and efficient production in the cell therapy industry.

Comparison to Industry Standards

• INB-200's median progression-free survival (mPFS) of 16.1 months in multiple-dose glioblastoma patients significantly exceeds the 6.9 months typically observed with the standard-of-care Stupp protocol, demonstrating superior efficacy in this challenging indication.
• The four-year progression-free survival milestone in a front-line, grade IV glioblastoma patient is a rare and highly positive outcome, indicating exceptional durability compared to typical outcomes in this aggressive cancer.

Stakeholder Impact

• **Shareholders**: Positive impact due to strong clinical data, reduced net loss, extended cash runway, and promising pipeline developments, potentially leading to increased share value.
• **Patients**: Significant positive impact, especially for glioblastoma patients, with the potential for extended progression-free survival and a safer treatment alternative for autoimmune diseases.
• **Employees**: Continued employment and potential for growth given the positive clinical progress and extended financial runway.
• **Creditors**: Improved financial health and extended cash runway reduce immediate liquidity concerns.

Next Steps

• Update on enrollment in INB-100 expansion cohort in leukemia patients.
• Glioblastoma clinical update from INB-200 and INB-400 clinical trials.
• Additional preclinical data from INB-619 T cell engager program for cancer and autoimmune diseases in Q4 2025.

Key Dates

Recommendation

The filing reveals exceptionally strong clinical data for INB-200 in glioblastoma, a notoriously difficult cancer, with a patient achieving four years of progression-free survival and the multiple-dose cohort showing more than double the mPFS of standard of care. This represents a significant de-risking event for the lead program. Coupled with a substantial reduction in net loss, improved cash position, and an extended cash runway into June 2026, the company demonstrates both scientific progress and financial prudence. The promising preclinical data for INB-619 in autoimmune diseases also opens up a new, large market opportunity. While there's a strategic pause on INB-400, the overall picture is highly positive for a clinical-stage biotech, suggesting strong potential for future value creation.

Keywords

gamma-delta T cell therapy, glioblastoma, GBM, autoimmune disease, INB-200, INB-619, DeltEx platform, clinical trial results, biopharmaceutical, oncology, lupus, cell therapy manufacturing, Nasdaq: INAB